Pfizer Vaccine Prevents 90% of Infections in Large Study

The transcript discusses the promising efficacy of a new RNA vaccine, which shows over 90% effectiveness. It compares this with other vaccines like measles and flu, highlighting the potential impact on COVID-19. The discussion includes Pfizer's next steps towards emergency use authorization and the challenges of vaccine rollout. The importance of safety data and the potential for future vaccine adaptations are also covered.

What was the primary aim of the trial for the new RNA vaccine?

• To test the vaccine on children

• To increase the production of antibodies

• To reduce symptoms like cough and fever

• To completely eradicate the virus

How does the efficacy of the new RNA vaccine compare to that of the flu vaccine?

• It is significantly higher

• It is not comparable

• It is about the same

• It is significantly lower

What is a key advantage of RNA vaccine technology mentioned in the discussion?

• It is cheaper to produce

• It requires no refrigeration

• It is more effective in children

• It can be quickly adapted to new virus strains

What is Pfizer's next step after gathering data from 94 cases?

• To distribute the vaccine globally

• To conduct more trials

• To seek emergency use authorization

• To start mass production

Why is it important to continue wearing masks and maintaining distance even after the vaccine rollout?

• The vaccine is only for healthcare workers

• The vaccine is not effective

• The virus has mutated

• The vaccine supply is limited initially